Kiora Pharmaceuticals posts 2025 net loss as expenses rise

Kiora Pharmaceuticals

25/03/2026 11:10

Overview

US retinal disease biotech posted 2025 net loss, reversing prior yr profit

R&D and G&A expenses rose in 2025, mainly due to clinical trial activity and personnel

Company ended 2025 with $17.1 mln in cash, expects runway into late 2027

Outlook

Company expects existing cash to fund operations into late 2027

Result Drivers

CLINICAL TRIAL ACTIVITY - Higher R&D expenses were mainly driven by clinical trial activities for KIO-301 and KIO-104

PERSONNEL COSTS - G&A expenses rose due to personnel and associated activities

NON-CASH IMPAIRMENT - Q4 net loss was mainly due to a non-cash impairment charge related to KIO-104

Company press release: ID:nNFC3Z3WXl

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY Net Income
-$10.8 mln


Analyst Coverage

The one available analyst rating on the shares is "buy"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Kiora Pharmaceuticals Inc is $12.00, about 482.5% above its March 24 closing price of $2.06

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)